Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL29116606 | 1.00 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL448070 | 0.98 | CA12 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| Methane SCHEMBL11212880 | 0.98 | CA12 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL23878412 | 0.98 | CA12 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| Methane SCHEMBL6569490 | 0.98 | CA12 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL23878452 | 0.98 | CA12 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL702199 | 0.98 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3367103 | 0.98 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| Ethane SCHEMBL5931998 | 0.96 | CA12 (0.55) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL23878485 | 0.96 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | ALCON INC. (CH) | 2026-02-03 | — | — | US | claimed |
| EP-4514595-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2025-03-05 | — | — | EP | claimed |
| EP-4240578-B1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | ALCON INC (CH) | 2024-12-18 | — | — | EP | claimed |
| US-11886045-B2 | Method for making photochromic contact lenses | ALCON INC. (CH) | 2024-01-30 | — | — | US | claimed |
| WO-2023209570-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2023-11-02 | — | — | WO | claimed |
| US-20230339149-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2023-10-26 | — | — | US | claimed |
| EP-4240578-A1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | Alcon Inc. (CH) | 2023-09-13 | — | — | EP | claimed |
| WO-2022097048-A1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | ALCON INC. (CH) | 2022-05-12 | — | — | WO | claimed |
| US-20220137433-A1 | METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES | ALCON INC. (CH) | 2022-05-05 | — | — | US | claimed |
| US-9138383-B1 | Nanogel materials and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-09-22 | — | — | US | claimed |
| CN-102180845-A | Butenolide structure-containing benzyl amino dithio formiate compounds, and preparation method and application thereof | UNIV ZHENGZHOU | 2011-09-14 | — | — | CN | claimed |
| US-7659321-B2 | Photoinitiator anchored to silicate and use thereof to prepare polymer exfoliated silicate nanocomposite | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-02-09 | — | — | US | claimed |
| US-20090012199-A1 | Photoinitiator anchored to silicate and use thereof to prepare polymer exfolidated silicate nanocomposite | NATIONAL SCIENCE FOUNDATION | 2009-01-08 | — | — | US | claimed |
| JP-2007517119-A | — | — | 2007-06-28 | — | — | JP | claimed |
| US-20070145625-A1 | Process for crosslinking free-radical crosslinkable polymers | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-06-28 | — | — | US | claimed |
| EP-1699881-A2 | FREE-RADICAL CROSSLINKABLE POLYMERS: IMPROVED PROCESS FOR CROSSLINKING AND COMPOSITIONS | The Dow Global Technologies Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2006055372-A2 | PHOTOINITIATOR ANCHORED TO SILICATE AND USE THEREOF TO PREPARE POLYMER EXFOLIATED SILICATE NANOCOMPOSITE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| WO-2005066280-A2 | FREE-RADICAL CROSSLINKABLE POLYMERS: IMPROVED PROCESS FOR CROSSLINKING AND COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-6265499-B1 | POLYMERIZING MIXTURE | MENICON CO., LTD. (JP) | 2001-07-24 | — | — | US | claimed |
| US-3962304-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | INF2, CRYZ, CRYAA | CA12 1690/4885CA1 1662/4885CA2 3767/4885 |
| US-20090012199-A1 | Photoinitiator anchored to silicate and use thereof to prepare polymer exfolidated silicate nanocomposite | MSN, NAPA, SELE | CA12 3154/4885CA1 2834/4885CA2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.